Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pemigatinib · Pemazyre, INCB054828

Small molecule · Inhibitor of fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 (FGFR2) and fibroblast growth factor receptor 3 (FGFR3) · developed by Incyte

Approved FDA, Apr 2020
INCY Developer
1 Registered trials

What is Pemigatinib?

Pemigatinib is a small molecule kinase inhibitor that targets FGFR1, FGFR2 and FGFR3, and inhibits FGFR4 at higher concentrations. It blocks constitutive FGFR signaling driven by activating fusions and amplifications, reducing malignant cell proliferation and survival. It is used in cholangiocarcinoma with FGFR2 rearrangement and in myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Pemazyre, INCB054828, PEMAZYRE
Drug type
Small molecule
Targets
fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 (FGFR2), fibroblast growth factor receptor 3 (FGFR3), fibroblast growth factor receptor 4 (FGFR4) (secondary target)
Mechanism
Inhibitor of fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 (FGFR2) and fibroblast growth factor receptor 3 (FGFR3)
Pathways
FGFR signaling, cell proliferation and survival
Therapy area
Oncology
Developer
Incyte Corp (INCY)
FDA status
Approved as Pemazyre (April 17, 2020), NDA213736 · FDA label
UNII
Y6BX7BL23K

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 9, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03914794 Phase 2 Bladder Cancer Active not recruiting INCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

FGFR2 Gene MutationFGFR2 Gene RearrangementIntrahepatic Cholangiocarcinoma

Other drugs acting on FGFR1 / FGFR2 / FGFR3

More from Incyte

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind Pemigatinib

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.